Novel Adjuvant Therapy for Ocular Melanoma
Bosch JJ, Heindl LM (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 234
Pages Range: 670-673
Journal Issue: 5
Abstract
Background Malignant melanoma is the most common cancer of the eye in adults that originates either in the intra-ocular uveal tract or extra-ocular conjunctiva. Although the primary tumor can be treated successfully, no effective therapy for both metastatic conjunctival and uveal melanoma currently exits. Tumor-associated lymphangiogenesis and immune cell infiltration play a pivotal role in the development and therapeutic targeting of metastases. Project description Here, we provide an overview of current translational research on lymphangiogenesis and its therapeutic inhibition as well as modulation of immune cell infiltration by passive and active immunotherapy in melanoma of the eye. Specifically, our previous and ongoing work on lymphangiogenesis and immune cells in ocular melanoma within the clinical research unit FOR 2240 "(Lymph)Angiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye" is summarized. Conclusions Translational research on the modulation of tumor-associated lymphangiogenesis and immune cell infiltration could provide novel targets for adjuvant therapy in melanoma of the eye.
Involved external institutions
Germany (DE)How to cite
APA:
Bosch, J.J., & Heindl, L.M. (2017). Novel Adjuvant Therapy for Ocular Melanoma. Klinische Monatsblätter für Augenheilkunde, 234(5), 670-673. https://doi.org/10.1055/s-0043-107807
MLA:
Bosch, Jacobus J., and Ludwig M. Heindl. "Novel Adjuvant Therapy for Ocular Melanoma." Klinische Monatsblätter für Augenheilkunde 234.5 (2017): 670-673.
BibTeX: Download